Analyzing immune responses to COVID-2019 vaccination using single-cell techniques
Evolution of Immune System in Healthy Adults After Vaccination of New Coronavirus (COVID-2019) Inactivated Vaccine Based on Single Cell Multi-Omics Technologies
RenJi Hospital · NCT04871932
This study is testing how healthy adults' immune systems respond to the COVID-19 vaccine using advanced techniques to better understand the different types of immune cells involved.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 50 Years |
| Sex | All |
| Sponsor | RenJi Hospital (other) |
| Locations | 1 site (Shanghai) |
| Trial ID | NCT04871932 on ClinicalTrials.gov |
What this trial studies
This observational study aims to recruit healthy adults aged 18 to 50 to analyze the immune response to COVID-2019 vaccination through advanced single-cell multi-omics techniques. By utilizing single-cell RNA sequencing, the study will classify peripheral blood mononuclear cells (PBMCs) to gain insights into immune cell heterogeneity and functionality. The research focuses on understanding the variations in immune cell populations and their potential implications for disease-related research. The findings could enhance our understanding of the immune system's response to vaccination.
Who should consider this trial
Good fit: Ideal candidates for this study are healthy adults aged 18 to 50 with no significant medical history or current infections.
Not a fit: Patients with infectious diseases, autoimmune disorders, or a history of major health issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the immune response to COVID-2019 vaccination, potentially leading to improved vaccine strategies.
How similar studies have performed: Other studies utilizing single-cell sequencing have shown promise in understanding immune responses, indicating that this approach is both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1\. Age from 18 to 50 years; 2. No history of major diseases, no history of bacterial or viral infection in the past 3 months; 3. No recent history of surgery or trauma; 4 No history of smoking or alcoholism; 5. No immune system disease. Exclusion Criteria: 1\. Infectious diseases; 2. Tumor diseases; 3. Hematological diseases; 4. History of hypertension and diabetes; 5 Autoimmune diseases; 6 History of liver and kidney insufficiency; 7. History of previous cardiovascular diseases; 8. Pregnancy Or breast-feeding; 9. Past and current use of immunosuppressive drugs
Where this trial is running
Shanghai
- Cardiology, Ren Ji Hospital — Shanghai, China (RECRUITING)
Study contacts
- Principal investigator: Jun Pu, MD,PhD — Cardiology, Ren Ji Hospital Shanghai, China
- Study coordinator: Jun Pu, MD,PhD
- Email: pujun310@hotmail.com
- Phone: 86-21-68383477
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Immune System and Related Disorders, Cohort study, Immune System, PBMC, China